How is peptide purity actually measured?

Purity is measured by reversed-phase high-performance liquid chromatography (RP-HPLC) against a validated method (USP ). The instrument separates the sample into its components by how strongly each interacts with the column, a detector records each as a peak, and purity is reported as area-percent: the main peak's area divided by the total area of all peaks. So "98% purity" means the target peptide accounts for 98% of the total detected peak area, not that the vial is 98% peptide by weight.

What does mass spectrometry tell you that HPLC doesn't?

HPLC measures how much of the sample is the main peak; it does not prove that peak is the right molecule. Mass spectrometry answers identity: it ionizes the peptide and measures its mass-to-charge ratio, from which software derives the molecular weight. You compare the observed mass to the peptide's theoretical mass (for retatrutide, about 4731 Da), and a match within a fraction of a percent confirms you have the intended compound and not a same-purity lookalike.

What does ≥98% purity actually mean for a peptide?

It means that on the HPLC chromatogram, the target peptide's peak represents at least 98% of the total detected peak area, leaving up to 2% as other peaks. It is a real quality benchmark (≥99% is achievable for well-made GLP-1-class peptides), but it says nothing about what the remaining fraction is. Under ICH Q3A, impurities above roughly 0.1% are expected to be identified, so a characterized 98.5% is stronger evidence than a "99%" figure with an unexamined 1%.

Electrospray ionization mass spectrometry (ESI-MS) is the mass-spec technique most used for peptides. It sprays the sample through a charged nozzle, producing a series of multiply-charged ions; software deconvolutes that series of peaks into a single molecular weight. It is favored for large peptides like retatrutide because it handles high molecular weights and couples directly to an HPLC (LC-MS), letting identity and purity be measured in one run.

Why do peptide reports mention TFA and acetate?

Both are counterions: the salt paired with the peptide. Trifluoroacetic acid (TFA) is used in RP-HPLC mobile phases during purification and can remain bound to the peptide; many suppliers exchange it for acetate because residual TFA can affect cell assays. The counterion plus residual water is real vial weight that is not peptide, so together they can account for 10–20% of a lyophilized vial, which is why a purity chromatogram and a weight-basis (acetate/water) are two different questions.

Can a peptide be 99% pure and still be the wrong molecule?

Yes. Purity by HPLC only describes what fraction of the sample is the main peak; it does not verify the main peak's identity. A 99%-pure sample of a mis-synthesized or mislabeled peptide will still read 99% pure. That is exactly why mass spectrometry is not optional: it is the identity gate that has to pass before a purity number means anything.

Peptide Purity Testing Explained: HPLC, Mass Spec & What Purity % Means

Quick answer

Peptide purity is measured by RP-HPLC and reported as area-percent: the main peak's area over the total peak area (USP <621>). ^[1] A "98% purity" figure means 98% of the detected peak area, not 98% of the vial by weight.
Mass spectrometry answers a different question: identity. It measures the peptide's molecular weight (for retatrutide, ~4731 Da) so you know the main peak is the right molecule. ^[3] HPLC without MS can certify a pure sample of the wrong compound.
≥98% is the quality benchmark for injectable-intent research peptides, but the number only matters if the remaining fraction is characterized. Under ICH Q3A, impurities above ~0.1% should be identified. ^[4]
This guide drills into the two lab methods behind every purity claim: what the chromatogram and the mass-spec trace show, what the percentage hides, and how numbers mislead.

Every peptide certificate of analysis leads with a purity percentage, and almost every buyer stops reading there. That single number is the output of two very different laboratory measurements: one that says how much of the sample is the target peptide, and one that says whether the target peptide is even the right molecule. Understanding what each method actually measures is the difference between trusting a number and being able to audit it.

This is a drill-down into those two methods, reversed-phase HPLC and mass spectrometry, the workhorses behind every legitimate purity claim. It is the companion to our field-by-field walk-through of the whole document in how to read a peptide COA; here we go deeper on the two assays that produce the headline figures. It is written for research and educational purposes; the compounds discussed are supplied for academic and pre-clinical study and are not approved for human use.

How peptide purity is actually measured

Two instruments do the heavy lifting, and they answer two separate questions. Confusing them is the single most common reason a buyer over-trusts a purity number.

The two methods behind every purity claim

Method	Question it answers	What it reports	Standard / technique
RP-HPLC	How much of the sample is the target?	Purity as area-percent	USP <621>; reversed-phase column ^[1]
Mass spectrometry	Is the target the right molecule?	Observed vs theoretical molecular weight	ESI-MS / MALDI-TOF ^[3]
HPLC related-substances	What is the non-target fraction?	Named, quantified impurity peaks	ICH Q3A thresholds ^[4]

Read the table as a sequence, not a menu. Identity (mass spec) comes first because a purity percentage is meaningless if the molecule being measured is the wrong one. Purity (HPLC) comes second. The impurity accounting comes third, because it is what turns a bare percentage into evidence. A report that gives you only the middle row, a number with no mass confirmation and no impurity breakdown, has answered the least important of the three questions.

I spent most of my first year sourcing research peptides doing what everyone does: sorting supplier PDFs by the purity number and buying the highest one. It felt rigorous. It wasn't: I was ranking suppliers on the one figure that is easiest to type and hardest to verify from a screenshot.

The habit changed when I finally sat down with an analytical chemist at a conference and asked her to walk me through an actual chromatogram. She covered the "99.4%" at the top of the page with her thumb and made me read the trace instead: one tall peak, and then a little shoulder riding up the back of it that the software had folded into the main peak's area. "That's a co-eluting impurity," she said. "Your number counted it as product." Then she pulled the mass-spec trace and overlaid the observed mass on the theoretical: about 4731 daltons for retatrutide, matching to the decimal. That was the part that actually confirmed I had the right compound.

Now my routine is fixed. Mass first: does the observed molecular weight land on the theoretical value? Then the HPLC baseline: is the main peak sharp and symmetric, or is something hiding in the tail? Only then do I read the percentage. It adds maybe ten minutes per lot and it has cost two suppliers my business, both of whom printed a great number over a trace that didn't support it.

— Warren Petrakis, Cincinnati, OH

What "purity" means: area-under-the-curve on a chromatogram

When a report says 98% purity, that figure is almost always an HPLC area-percent. The peptide is pushed through a chromatography column that separates it from everything else in the vial; a detector on the far end records a signal every time something elutes, drawing a chromatogram: a plot of detector signal against time, with a peak for each distinct species. Software integrates the area under each peak, and purity is the main peak's area divided by the total area of all peaks, times 100. ^[1]

That definition is the whole game. Purity is a ratio of peak areas, not a mass fraction of the vial. A 98% area-percent means the target peptide accounts for 98% of the detected signal, and the remaining 2% is one or more other peaks the same run detected but the headline number did not name. It says nothing directly about how much water or salt is in the vial (those are separate weight-basis measurements) and nothing about whether the main peak is the correct molecule (that is mass spec). It is a precise answer to a narrow question: of the things this detector saw, what share was the one you wanted.

How RP-HPLC separates a peptide from its impurities

The "RP" is reversed-phase, and it is the reason HPLC can resolve a peptide from impurities that differ from it by a single amino acid. The column is packed with a nonpolar (hydrophobic) stationary phase, usually C18 chains bonded to silica. The sample is carried through in a mobile phase whose organic content (typically acetonitrile) is increased over the run, a gradient. Molecules partition between the two phases according to how hydrophobic they are: more polar species wash off the column early, more hydrophobic ones are retained longer and elute later. ^[2]

This is why RP-HPLC is so discriminating for peptides. Synthesis errors, such as a deletion sequence missing one residue, a truncated chain, or an oxidized or deamidated variant, usually have a slightly different hydrophobicity than the correct peptide, so they leave the column at a slightly different time and show up as their own peaks. A well-developed method spreads these apart enough to integrate them separately, which is exactly what lets the impurity fraction be named rather than swept into the main peak.

The mobile phase itself matters for a reason that surfaces later on the COA: RP-HPLC of peptides classically uses trifluoroacetic acid (TFA) as an ion-pairing additive because it sharpens peaks. That same TFA can stay bound to the peptide as a counterion, which is why "residual TFA" and "acetate exchange" appear on quality documents, a purification artifact of the very method used to measure purity. ^[5]

Reading the chromatogram: main peak, shoulders, and baseline

The percentage is a summary; the chromatogram is the evidence. Once you can read the trace, you can see things the number hides.

Reading an HPLC chromatogram

What you see	What it means
One tall, sharp, symmetric main peak	Clean target; the bulk of the signal is one species
A flat, quiet baseline	Little background; impurities aren't being lost in noise
Small peaks flanking the main peak	Related impurities, often deletion/truncation sequences
A shoulder on the main peak	A co-eluting species partly hidden inside the "pure" area
A broad or tailing main peak	Possible co-elution or column/method issues
A sloping or noisy baseline	Integration is less reliable; small peaks may be masked

A good trace is boring in the best way: one dominant peak, sharp and symmetric, on a flat baseline. The concerning patterns are the interesting ones. A shoulder (a bump riding up the side of the main peak) is a species eluting at almost the same time, and depending on where the software draws the peak boundary, its area may be counted as the main peak, inflating purity. A cluster of small satellite peaks is the impurity profile made visible; whether that is fine or alarming depends entirely on whether those peaks are identified. A bare percentage with no chromatogram attached asks you to trust the integration without seeing the data it was computed from, which is the one thing a low-quality supplier can produce without earning it.

What ≥98% purity does and doesn't tell you

There is a genuine benchmark here, and there is a more important caveat that sits right behind it.

Reading a peptide purity figure

Purity (HPLC area-%)	Typical reading	The caveat
≥99%	Excellent for a GLP-1-class research peptide	Only if the impurities are named
98–99%	Solid quality benchmark	Confirm the missing 1–2% is characterized
95–98%	Acceptable for some applications	Ask what the extra peaks actually are
<95%	Below common research grade	Impurity load high enough to affect data

What ≥98% tells you: most of the detected signal is the target peptide, and for injectable-intent research peptides ≥98% is the common quality floor, with ≥99% achievable for well-synthesized GLP-1-class compounds. That is a real, meaningful bar, and material well below it carries an impurity load that can confound whatever you are measuring downstream.

What it does not tell you: what the other 1–2% is. Under ICH Q3A, impurities in a drug substance are expected to be reported above roughly 0.05%, identified above roughly 0.1%, and qualified above roughly 0.15%. ^[4] Translated to a purity report, any impurity peak of meaningful size should be named, not left as an anonymous remainder. This is the reframing that matters most.

Two lots can both read "99%" and be different products. The percentage tells you how much is not the target; the impurity profile tells you what that fraction is. A characterized, process-related impurity at 0.4% is a very different thing from a 1% peak nobody can name.

Mass spectrometry: confirming identity and molecular weight

HPLC tells you how much of the sample is the main peak. It cannot tell you the main peak is the right molecule: a 99%-pure sample of a mis-synthesized peptide still reads 99% pure. That gap is filled by mass spectrometry, which measures the mass-to-charge ratio of the ionized molecule and, from it, the molecular weight. ^[3]

The report gives you two numbers to compare directly: the theoretical (calculated) molecular weight of the peptide from its sequence, and the observed mass from the instrument. For a correct molecule these agree to within a fraction of a percent. Retatrutide's theoretical mass is about 4731 Da; an observed value landing on that number confirms the identity, while a mismatch, even with a beautiful purity trace, means you have a pure sample of something else.

ESI-MS (electrospray ionization) is the technique most used for peptides this size. It sprays the sample through a charged nozzle to produce a series of multiply-charged ions, so the raw spectrum is a ladder of peaks that software deconvolutes into one molecular weight. Its two practical advantages are that it handles high molecular weights gracefully and couples directly to an HPLC, an LC-MS run measures purity and identity in a single pass. MALDI-TOF is the alternative, typically showing the singly-charged molecular ion more directly and tolerating impure samples well. Either is valid; what you want on the report is the observed value and, ideally, the trace behind it.

The identity check is a gate, not a footnote. A report that gives purity but omits mass confirmation has skipped the one measurement that says what you are looking at, which is why we treat any purity number that arrives without a mass-spec identity as structurally incomplete.

HPLC vs mass spec: two questions, two answers

Because these methods are so easily conflated, it is worth stating the division of labor plainly.

Purity (HPLC) vs identity (mass spec)

	RP-HPLC	Mass spectrometry
Answers	"How much is the target?"	"Is it the right molecule?"
Reports	Purity as area-percent	Molecular weight (Da)
Catches	Impurities, related substances	Wrong sequence, mislabeled compound
Misses	Whether the main peak is correct	The relative quantity of impurities
Together	Purity of a confirmed molecule	N/A

Neither is sufficient alone. HPLC can certify a highly pure sample of the wrong peptide; mass spec can confirm the right peptide is present without telling you how much of the vial is impurity. A trustworthy report runs both, and, better still, runs them together as LC-MS so the mass is measured on the very peak the purity number describes.

Purity and identity are only two of the questions a full quality document answers. Several others are separate measurements the chromatogram and mass spectrum say nothing about, and they are where a "high purity" vial can still fall short.

Water content: Lyophilized peptides hold residual moisture, measured by loss on drying (USP <731>) or Karl Fischer titration, commonly a few percent by weight. ^[6] It is real vial mass that is not peptide.
Acetate / counterion content: The peptide ships as a salt; the acetate (or other) counterion is part of net weight and is quantified by ion chromatography or titration. ^[5]
Residual TFA: Left over from the HPLC mobile phase used in purification; many suppliers exchange it for acetate because residual TFA can interfere with cell-based assays. ^[5]
Endotoxin: Bacterial pyrogens detected by the LAL assay under USP <85>, reported against a stated limit for injectable-intent material. ^[7] Neither HPLC nor MS detects it.

The weight-basis point is the one most often missed. Because water plus counterion can total 10–20% of a lyophilized vial's mass, a "99% pure" peptide is 99% pure on the chromatogram while the vial itself is materially less than 99% peptide by weight. The purity figure and the amount of active compound are simply two different measurements. We break the full field list down in how to read a peptide COA.

Common ways a purity number misleads

Once you know how the number is produced, the ways it gets inflated or oversold become predictable.

Counting a shoulder as product: A co-eluting species that rides inside the main peak gets its area folded into "purity" unless the method resolves it and the analyst integrates it separately.
A percentage with no chromatogram: The headline is trivial to type and impossible to audit without the trace. No trace, no verification.
Purity without identity: A gorgeous 99.5% on a molecule no mass spectrum ever confirmed. The number is real; the compound is unverified.
An anonymous remainder: "99% pure" printed above a blank where the impurity breakdown should be. ICH Q3A expects the meaningful impurities named; silence is a gap, not a clean bill. ^[4]
Confusing area-percent with weight-percent: Reading "99%" as "the vial is 99% peptide," ignoring the water and counterion that are not peptide at all.
A frozen result across lots: The identical purity figure and impurity table on every batch, for months. Real chromatography varies run to run; a number that never moves is a template.

None of these requires your own lab to catch. They require reading the number as a claim that must be backed by a chromatogram, a mass spectrum, and an impurity table that reconcile with each other.

Third-party vs in-house testing

Every purity number is produced by someone, and who that someone is changes what the number is worth. An in-house result comes from the manufacturer's own quality lab. The methods are legitimate, the same RP-HPLC and mass spectrometry an independent lab would run, but the party being graded is also the party reporting the grade. That does not make in-house numbers fraudulent; it makes them unaudited.

A third-party result comes from an independent analytical lab with no stake in the outcome. Same instruments, different incentive. Independent testing is the only step that confirms a self-reported figure, which is why serious sourcing treats the manufacturer's number as a starting point and an independent retest as the verdict. Our own standard re-runs identity and purity at a lab the manufacturer does not use, across two separate lots. The full process is in how we vet a new manufacturer, and it is the same lens to apply when deciding what to look for when buying retatrutide.

How to sanity-check a trace yourself

You do not need an analytical lab to do meaningful verification. A short sequence catches most problems:

Confirm identity first: Compare the observed molecular weight on the mass spectrum to the peptide's theoretical mass (retatrutide ≈ 4731 Da). They should agree to a fraction of a percent. If there is no mass at all, stop. Purity without identity is unverified.
Read the chromatogram, not just the number: Look for one sharp, symmetric main peak on a flat baseline. Scan the tail of the main peak for a shoulder.
Reconcile the arithmetic: Purity plus total named impurities should sum to ~100%. An unexplained remainder is a red flag.
Check the largest impurity is named: Under ICH Q3A, a meaningful impurity peak should be identified, not anonymous. ^[4]
Separate purity from weight: Look for water and counterion (acetate/TFA) lines so you know how much of the vial is actually peptide.
Note who tested it: A named, dated, signed report, ideally from an independent lab, is auditable; an anonymous one is not.

Run in that order, these checks take a few minutes and separate a report that earned its number from one that merely printed it. The same compound this guide uses for its worked figures is covered end to end in the complete retatrutide guide.

Frequently asked questions

How is peptide purity actually measured?: Purity is measured by reversed-phase high-performance liquid chromatography (RP-HPLC) against a validated method (USP <621>). The instrument separates the sample into its components by how strongly each interacts with the column, a detector records each as a peak, and purity is reported as area-percent: the main peak's area divided by the total area of all peaks. So '98% purity' means the target peptide accounts for 98% of the total detected peak area, not that the vial is 98% peptide by weight.
What does mass spectrometry tell you that HPLC doesn't?: HPLC measures how much of the sample is the main peak; it does not prove that peak is the right molecule. Mass spectrometry answers identity: it ionizes the peptide and measures its mass-to-charge ratio, from which software derives the molecular weight. You compare the observed mass to the peptide's theoretical mass (for retatrutide, about 4731 Da), and a match within a fraction of a percent confirms you have the intended compound and not a same-purity lookalike.
What does ≥98% purity actually mean for a peptide?: It means that on the HPLC chromatogram, the target peptide's peak represents at least 98% of the total detected peak area, leaving up to 2% as other peaks. It is a real quality benchmark (≥99% is achievable for well-made GLP-1-class peptides), but it says nothing about what the remaining fraction is. Under ICH Q3A, impurities above roughly 0.1% are expected to be identified, so a characterized 98.5% is stronger evidence than a '99%' figure with an unexamined 1%.
What is ESI-MS?: Electrospray ionization mass spectrometry (ESI-MS) is the mass-spec technique most used for peptides. It sprays the sample through a charged nozzle, producing a series of multiply-charged ions; software deconvolutes that series of peaks into a single molecular weight. It is favored for large peptides like retatrutide because it handles high molecular weights and couples directly to an HPLC (LC-MS), letting identity and purity be measured in one run.
Why do peptide reports mention TFA and acetate?: Both are counterions: the salt paired with the peptide. Trifluoroacetic acid (TFA) is used in RP-HPLC mobile phases during purification and can remain bound to the peptide; many suppliers exchange it for acetate because residual TFA can affect cell assays. The counterion plus residual water is real vial weight that is not peptide, so together they can account for 10–20% of a lyophilized vial, which is why a purity chromatogram and a weight-basis (acetate/water) are two different questions.
Can a peptide be 99% pure and still be the wrong molecule?: Yes. Purity by HPLC only describes what fraction of the sample is the main peak; it does not verify the main peak's identity. A 99%-pure sample of a mis-synthesized or mislabeled peptide will still read 99% pure. That is exactly why mass spectrometry is not optional: it is the identity gate that has to pass before a purity number means anything.

Glossary

RP-HPLC: Reversed-phase high-performance liquid chromatography, separates a peptide from its impurities by hydrophobicity to measure purity as area-percent.
Chromatogram: The HPLC output plot: detector signal against elution time, with one peak per distinct species in the sample.
Area-percent purity: The main peak's area divided by the total area of all peaks in the chromatogram, the standard peptide purity figure.
Mass spectrometry: An analytical method that confirms molecular identity by measuring the mass-to-charge ratio of ionized molecules (e.g. ESI-MS, MALDI-TOF).
ESI-MS: Electrospray ionization mass spectrometry, produces multiply-charged ions that are deconvoluted into one molecular weight; standard for peptides.
Deconvolution: The software step that collapses an ESI-MS ladder of multiply-charged peaks into a single molecular-weight value.
Deletion sequence: A synthesis-error impurity missing one amino acid, which usually elutes as its own HPLC peak near the target.
Counterion: The salt (acetate or TFA) paired with a synthetic peptide; part of net weight, so it must be subtracted to know true peptide mass.
TFA: Trifluoroacetic acid, an RP-HPLC mobile-phase additive that can remain bound to the peptide as a counterion; often exchanged for acetate.
ICH Q3A: The impurities guideline defining reporting (~0.05%), identification (~0.10%), and qualification (~0.15%) thresholds for a drug substance.

References

United States Pharmacopeia (USP). General Chapter <621> Chromatography — HPLC separation and area-percent purity determination.
Mant CT, Hodges RS (eds). HPLC of Peptides and Proteins: Separation, Analysis, and Conformation. CRC Press, 2002 — reversed-phase separation of peptides.
de Hoffmann E, Stroobant V. Mass Spectrometry: Principles and Applications, 3rd ed. Wiley, 2007 — ESI and MALDI identity confirmation of peptides.
ICH Q3A(R2). Impurities in New Drug Substances — reporting (~0.05%), identification (~0.10%), and qualification (~0.15%) thresholds.
Roux S, Zékri E, Rousseau B, et al. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation. Journal of Peptide Science. 2008;14(3):354-359.
United States Pharmacopeia (USP). General Chapter <731> Loss on Drying — residual moisture determination.
United States Pharmacopeia (USP). General Chapter <85> Bacterial Endotoxins Test (LAL assay).

For research and educational purposes only. Not medical advice. Purity and identity testing characterize the contents of a specific lot; they do not make an investigational compound approved or safe for human use. Illustrative chromatogram and mass figures are teaching values, not a specific shipped lot. These compounds are supplied for academic and pre-clinical study and are not approved for human use.